top of page

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

Tucson, AZ, July 29, 2021 --( NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.

Click here to read more

Recent Posts

See All

Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In th

bottom of page